Vasoinhibin, an N-terminal Prolactin Fragment, Directly Inhibits Cardiac Angiogenesis in Three-dimensional Heart Culture.
Vasoinhibins (Vi) are fragments of the growth hormone/prolactin (PRL) family and have antiangiogenic functions in many species. It is considered that Vi derived from PRL are involved in the pathogenesis of peripartum cardiomyopathy (PPCM). However, the pathogenic mechanism of PPCM, as well as heart angiogenesis, is not yet clear. Therefore, the aim of the present study is to clarify whether Vi act directly on angiogenesis inhibition in heart blood vessels. Endothelial cell viability was decreased by Vi treatment in a culture experiment. Furthermore, expression of proangiogenic genes, such as vascular endothelial growth factor, endothelial nitric oxide synthase, and VE-cadherin, were decreased. On the other hand, apoptotic factor gene, caspase 3, and inflammatory factor genes, tumor necrosis factor α and interleukin 6, were increased by Vi treatment. In three-dimensional left ventricular wall angiogenesis assay in mice, Vi treatment also inhibited cell migration, neovessel sprouting, and growth toward collagen gel. These data demonstrate that Vi treatment directly suppresses angiogenesis of the heart and support the hypothesis that Vi induce PPCM.
Laboratory of Functional Anatomy, Faculty of Agriculture, Department of Life Sciences, Meiji University , Kawasaki , Japan.
Ryojun
R
Nakajima
Laboratory of Functional Anatomy, Faculty of Agriculture, Department of Life Sciences, Meiji University , Kawasaki , Japan.
Eri
E
Nakamura
Laboratory of Functional Anatomy, Faculty of Agriculture, Department of Life Sciences, Meiji University , Kawasaki , Japan.
Toshio
T
Harigaya
angiogenesis; heart; peripartum cardiomyopathy; prolactin; vasoinhibin